CAS: 618-46-2; 3-Chlorobenzoylchloride

上下游产品

CAS号535-80-8 间氯苯甲酸 | CAS号98-88-4 苯甲酰氯 | CAS号3416-93-1 2-(4,5-dihydro-... | CAS号121-53-9 3-硫苯甲酸 | CAS号77-95-2 D-(-)-奎宁酸 | CAS号10026-13-8 五氯化磷 | CAS号105997-05-5 6-(3-chlorophen... | CAS号10286-92-7 3-Chloro-N-(3-c... | CAS号141-85-5 间氯苯胺盐酸盐 | CAS号35306-52-6 N-ALLYL-3-CHLOR... | CAS号33167-21-4 (3-氯苯甲酰)乙酸乙酯 | CAS号937-14-4 间氯过氧苯甲酸 | CAS号22868-29-7 2-(3-Chlorophen... | CAS号20651-70-1 Methyl 3-butylb... | CAS号34555-37-8 4-(3-CHLOROPHEN... | CAS号587-04-2 3-氯苯甲醛

3-氯苯甲酸乙酯置于lithium Hydroxide体系中,用 四氢呋喃,乙醇,水 作为反应溶剂,化学反应 4.0H,反应生成 3-氯苯甲酰氯
参考文献:哌隆定衍生的环磺酰胺(sultams):合成和体外探索对hela癌细胞系的治疗潜力
标题:哌隆定衍生的环磺酰胺(sultams):合成和体外探索对hela癌细胞系的治疗潜力
摘要:设计了带有环磺酰胺(sultam)的新的哌隆金变型,并对其合成进行了描述.我们首次在本文中通过闭环易位方法报道了使用格鲁布斯第二代催化剂(格鲁布斯ii)对天然产物衍生的环状磺酰胺的合成和生物学评估.使用维蒂希反应,闭环易位(rcm)和使用混合酸酐合成酰胺的方法,可以中等至非常好的产率合成一系列由哌啶子丁衍生的阿马甜.评估所有合成的化合物的抗癌活性,并证明其中一些剂量依赖性地降低了hela细胞的生长.在这些7,10和14中,细胞生长明显减少.因此,他们计算出的gi 50 发现该值是0.1或<0.1μm.
DOI:10.1016/j.Ejmech.2016.12.022

专利信息

专利号:US-7582758-B2
优先权日:2004-06-08
标 题:Lewis acid mediated synthesis of cyclic esters
发明人：MARTIN KEVIN V
权利人:METABASIS THERAPEUTICS INC
摘要:Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid.

专利号:US-11981648-B2
优先权日:2019-06-13
标题:Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones
发明人：HALL DAVID S; DAHN JEFFERY RAYMOND; HYNES TOREN
权利人:TESLA INC; PANASONIC HOLDINGS CORP
摘要:Provided are methods of preparing 3-R-1,4,2-dioxazol-5-one compounds using convenient and efficient methods. Also provided are 3-R-1,4,2-dioxazol-5-one compounds produced using the methods described.

专利号:US-3862209-A
优先权日:1972-05-12
标题:Process of making nitro phenoxybenzoic acid esters
发明人：THEISSEN ROBERT JAMES
权利人:MOBIL OIL CORP
摘要:Improved process for the synthesis of certain nitro phenoxybenzoic acid esters in which high yield, high purity, herbicidally effective compounds are obtained. In general the improvement comprises: 1. ESTERIFICATION OF A HALOBENZOYL HALIDE WITH ISOPROPANOL THEREBY FACILITATING SEPARATION OF ISOMERIC IMPURITIES FROM THE DESIRED ISOPROPYL-NITROBENZOATE ESTER INTERMEDIATE. 2. TRANSESTERIFICATION OF A PHENOXY DERIVATIVE OF SAID ESTER TO THE DESIRED PHENOXYBENZOIC ACID ESTER.

专利号:US-7071207-B2
优先权日:2001-09-24
标题 :Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
发明人：SMITH ROGER A; O'CONNOR STEPHEN J; WONG WAI C; CHOI SOONGYU; KLUENDER HAROLD C; FAN JIANMEI; ZHANG ZHONGHUA; LAVOIE RICO C; PODLOGAR BRENT L
权利人:BAYER PHARMACEUTICALS CORP
摘要:This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

专利号:US-2005009924-A1
优先权日:2003-07-08
标 题 :Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives
发明人：HUANG HSU-SHAN
摘要:This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: n n nwherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH 2 , —RNH 2 R, —ROH, —NO 2 , —OCH 3 , —OCH 2 CH 3 , and —OCH 2 CH 2 CH 3 ; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH 2 , —RNH 2 R, —ROH, —NO 2 , —OCH 3 , —OCH 2 CH 3 , —OCH 2 CH 2 CH 3 , —CH 2 Br, —CH 2 Cl, —CH 2 OH, —C(CH 3 ) 3 , —(CH 2 ) 2 0H, —(CH 2 ) 3 OH, —(CH 2 ) 4 OH, —CH 2 NH 2 , —(CH 2 ) 2 NH 2 , —(CH 2 ) 3 NH 2 , —(CH 2 ) 4 NH 2 , —(CH 2 ) 5 NH 2 , —CH 2 N(CH 3 ) 2 , —(CH 2 ) 2 N(CH 3 ) 2 , —(CH 2 ) 2 NH(CH 2 ) 2 OH, —(CH 2 ) 3 NH(CH 2 ) 2 OH, —(CH 2 ) 2 NHCH 2 OH, —(CH 2 ) 3 NHCH 2 OH, —CH 2 CH(CH 3 ) 2 , —CHCl 2 , —CH(CH 3 )Cl, —(CH 2 ) 2 Cl, —(CH 2 ) 3 Cl, —(CH 2 ) 3 Br, —(CH 2 ) 4 Br, and —(CH 2 ) 4 Cl. n n Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×10 7 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×10 5 /mL, and the SEAP activity after 24 h at 37 â–¡. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P<0.05 is presented by an asterisk.

专利号:US-2024287008-A1
优先权日:2019-06-13
标题 :Method for the synthesis of 3-r-1,4,2-dioxazol-5-ones